Novartis has agreed to acquire Sironax and its blood-brain barrier delivery platform, according to a report by AllSci dated September 16, 2026. The report states that Novartis exercised an option to acquire the platform for USD 125m.
The verified transaction facts list the purchase consideration as $0 USD. No further details on the structure, timing, or rationale of the agreement were provided in the available source material.